Wall Street analysts expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to post ($0.22) earnings per share for the current quarter, according to Zacks. Five analysts have made estimates for Dicerna Pharmaceuticals’ earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.43). Dicerna Pharmaceuticals posted earnings of ($0.30) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 26.7%. The firm is scheduled to issue its next earnings report on Monday, May 13th.
Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The firm had revenue of $1.54 million for the quarter, compared to the consensus estimate of $8.38 million. Dicerna Pharmaceuticals had a negative return on equity of 53.27% and a negative net margin of 1,438.68%.
Shares of NASDAQ:DRNA traded down $0.19 on Thursday, hitting $14.58. The company’s stock had a trading volume of 347,206 shares, compared to its average volume of 543,870. Dicerna Pharmaceuticals has a 1 year low of $9.31 and a 1 year high of $17.98. The stock has a market cap of $998.64 million, a P/E ratio of -12.15 and a beta of 2.42.
In other Dicerna Pharmaceuticals news, insider James B. Weissman sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $15.00, for a total value of $225,000.00. Following the sale, the insider now owns 39,480 shares of the company’s stock, valued at $592,200. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 19.85% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Dicerna Pharmaceuticals by 512.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,459 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 2,894 shares in the last quarter. Legal & General Group Plc raised its holdings in Dicerna Pharmaceuticals by 38.7% during the fourth quarter. Legal & General Group Plc now owns 9,186 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 2,561 shares in the last quarter. Bank of America Corp DE increased its holdings in Dicerna Pharmaceuticals by 30.3% in the fourth quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 2,465 shares in the last quarter. TD Asset Management Inc. purchased a new position in Dicerna Pharmaceuticals in the fourth quarter valued at about $169,000. Finally, State Board of Administration of Florida Retirement System increased its holdings in Dicerna Pharmaceuticals by 19.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 18,234 shares of the biopharmaceutical company’s stock valued at $195,000 after buying an additional 3,024 shares in the last quarter. Hedge funds and other institutional investors own 85.29% of the company’s stock.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Featured Article: Futures Contract
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.